PVLAPalvella Therapeutics Inc. Common Stock

Palvella Therapeutics (NASDAQ:PVLA) is advancing topical therapies for serious rare skin diseases and vascular malformations that lack FDA-approved treatments, with its lead candidate, QTORIN rapamycin, moving toward a planned New Drug Application submission for microcystic lymphatic malformations.

Rare skin disease biotech reports $250.6M cash, plans 2027 FDA approval for lead therapy.

Palvella Therapeutics stock has delivered a very strong 285.7% return over the past year, yet the latest valuation checks and stretched market multiples suggest the current price may already be baking in a lot of optimism. Palvella Therapeutics has returned 285.7% over the last 12 months, which puts extra focus on whether recent gains are supported by the fundamentals. Progress on the QTORIN rapamycin program, including the rolling New Drug Application and plans for a potential commercial...

Moby summary of Palvella Therapeutics, Inc.'s Q2 2026 earnings call

Palvella Therapeutics Inc (PVLA) reports robust QTORIN rapamycin results, a successful $230M capital raise, and on-track NDA submission for microcystic lymphatic malformations.

Palvella Therapeutics (NASDAQ:PVLA) said it remains on track to complete its new drug application submission for QTORIN rapamycin in microcystic lymphatic malformations, or mLM, during the second half of 2026, with potential FDA approval targeted for the first half of 2027. The company has submitte

Palvella Therapeutics Inc. (NASDAQ:PVLA) is one of the 10 affordable biotech stocks to buy right now. On June 29, Palvella Therapeutics Inc. (NASDAQ:PVLA) disclosed that it filed the initial module of its New Drug Application with the FDA for approval of QTORIN 3.9% rapamycin anhydrous gel. QTORIN is used to treat microcystic lymphatic malformations. The […]